Oscient Pharmaceuticals Corporation And Pfizer, S.A. de C.V. Announce Launch Of FACTIVE(R) Tablets In Mexico

WALTHAM, Mass. & MEXICO CITY--(BUSINESS WIRE)--FACTIVE(R) (gemifloxacin mesylate) tablets, Oscient Pharmaceuticals Corporation’s (Nasdaq: OSCI) lead antibiotic product, has been launched by Pfizer, S.A. de C.V. (Pfizer Mexico), the largest pharmaceutical company in Mexico. Pfizer Mexico is promoting FACTIVE-5 in Mexico for the five-day treatment of acute bacterial exacerbations of chronic bronchitis (AECB), acute bacterial sinusitis (ABS) and community-acquired pneumonia (CAP).

Back to news